166 related articles for article (PubMed ID: 12639293)
81. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.
Pribluda VS; Gubish ER; Lavallee TM; Treston A; Swartz GM; Green SJ
Cancer Metastasis Rev; 2000; 19(1-2):173-9. PubMed ID: 11191057
[TBL] [Abstract][Full Text] [Related]
82. Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate.
Ceaglio N; Etcheverrigaray M; Conradt HS; Grammel N; Kratje R; Oggero M
J Biotechnol; 2010 Mar; 146(1-2):74-83. PubMed ID: 20067809
[TBL] [Abstract][Full Text] [Related]
83. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12.
Yao L; Pike SE; Setsuda J; Parekh J; Gupta G; Raffeld M; Jaffe ES; Tosato G
Blood; 2000 Sep; 96(5):1900-5. PubMed ID: 10961892
[TBL] [Abstract][Full Text] [Related]
84. Antimyeloma efficacy of thalidomide in the SCID-hu model.
Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J
Blood; 2002 Dec; 100(12):4162-8. PubMed ID: 12393672
[TBL] [Abstract][Full Text] [Related]
85. Development of next generation of therapeutic IFN-α2b via genetic code expansion.
Zhang B; Xu H; Chen J; Zheng Y; Wu Y; Si L; Wu L; Zhang C; Xia G; Zhang L; Zhou D
Acta Biomater; 2015 Jun; 19():100-11. PubMed ID: 25769229
[TBL] [Abstract][Full Text] [Related]
86. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b.
Sirohi B; Powles R; Lawrence D; Treleaven J; Kulkarni S; Leary A; Rudin C; Horton C; Morgan G
Ann Oncol; 2007 Aug; 18(8):1388-94. PubMed ID: 17693652
[TBL] [Abstract][Full Text] [Related]
87. Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma.
Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J
Int J Exp Pathol; 2002 Apr; 83(2):99-104. PubMed ID: 12084046
[TBL] [Abstract][Full Text] [Related]
88. Clinical and interferon-modulating efficacy of a combination of rectal and topical dosage forms of interferon-α2b in acute respiratory infections.
Kalyuzhin OV; Ponezheva ZB; Kupchenko AN; Shuvalov AN; Guseva TS; Parshina OV; Malinovskaya VV; Akimkin VG
Ter Arkh; 2018 Nov; 90(11):48-54. PubMed ID: 30701815
[TBL] [Abstract][Full Text] [Related]
89. PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.
Kaminskas LM; Ascher DB; McLeod VM; Herold MJ; Le CP; Sloan EK; Porter CJ
J Control Release; 2013 Jun; 168(2):200-8. PubMed ID: 23499718
[TBL] [Abstract][Full Text] [Related]
90. Interferon alpha2b inhibits the murine melanoma cell line Cloudman S91 in vivo but not in vitro: a model for studying tumor cell-cytokine interactions.
Habib FA; Lobocki C; Ezhuthachan R; Chelladurai M; Preventza O; Mittal VK
Am Surg; 2001 Mar; 67(3):257-60. PubMed ID: 11270885
[TBL] [Abstract][Full Text] [Related]
91. [Effect of Interferon Combined with Thalidomid on HEL Cell Apoptosis and JAK2V617F Mutation Gene Expression].
Wu XX; Xue LG; Zhao LD; Wang Y; Cai ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):998-1002. PubMed ID: 27531763
[TBL] [Abstract][Full Text] [Related]
92. A novel snake venom disintegrin that inhibits human ovarian cancer dissemination and angiogenesis in an orthotopic nude mouse model.
Markland FS; Shieh K; Zhou Q; Golubkov V; Sherwin RP; Richters V; Sposto R
Haemostasis; 2001; 31(3-6):183-91. PubMed ID: 11910184
[TBL] [Abstract][Full Text] [Related]
93. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo.
Majewski S; Marczak M; Szmurlo A; Jablonska S; Bollag W
J Invest Dermatol; 1996 May; 106(5):1114-8. PubMed ID: 8618049
[TBL] [Abstract][Full Text] [Related]
94. The effect of thalidomide on experimental tumors and metastases.
Minchinton AI; Fryer KH; Wendt KR; Clow KA; Hayes MM
Anticancer Drugs; 1996 May; 7(3):339-43. PubMed ID: 8792009
[TBL] [Abstract][Full Text] [Related]
95. Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide.
Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y
Biol Pharm Bull; 1999 Feb; 22(2):224-6. PubMed ID: 10077449
[TBL] [Abstract][Full Text] [Related]
96. Influence of interferon-alpha2b (IFN-alpha2b) on the prevention of locally advanced bladder carcinoma in mice.
Otto T; Bex A; Lümmen G; Rübben H
Urol Res; 1999 Dec; 27(6):489-92. PubMed ID: 10651139
[TBL] [Abstract][Full Text] [Related]
97. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice.
Gołab J; Kozar K; Kamiński R; Czajka A; Marczak M; Switaj T; Giermasz A; Stokłosa T; Lasek W; Zagozdzon R; Mucha K; Jakóbisiak M
Life Sci; 2000 Feb; 66(13):1223-30. PubMed ID: 10737417
[TBL] [Abstract][Full Text] [Related]
98. Thalidomide failed to inhibit angiogenesis and fibrosis in hepatic schistosomiasis of the mouse.
Lima CB; Iglesias KB; Andrade ZA
Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):883-5. PubMed ID: 17992363
[TBL] [Abstract][Full Text] [Related]
99. Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice.
Farese JP; Fox LE; Detrisac CJ; Van Gilder JM; Roberts SL; Baldwin JM
Am J Vet Res; 2004 May; 65(5):659-64. PubMed ID: 15141888
[TBL] [Abstract][Full Text] [Related]
100. Studies on tumor induced angiogenesis.
Ambrus JL; Ambrus CM; Forgach P; Stadler S; Halpern J; Sayyid S; Niswander P; Toumbis C
EXS; 1992; 61():436-44. PubMed ID: 1377568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
